C4 Therapeutics shows a technical breakout and a perfect earnings beat streak, but extreme cash burn keeps quality below the engine's floor, the valuation looks rich against declining revenue, and short interest sits at a level the engine judges as fundamentally justified.
Thesis pillars
- Extreme Cash Burn Quality Risk→Stable
- Richly Valued Despite Declining Revenue→Stable
- High Short Interest Justified By Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
C4 Therapeutics, Inc. (CCCC) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $4.17: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.2/10. Specifically: High short interest: 20%; Elevated put/call ratio: 1.71; Below-average business quality.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company using its proprietary TORPEDO platform to design small-molecule targeted protein degraders, with two clinical programs — cemsidomide for multiple myeloma and CFT8919 for EGFR-mutant lung cancer (partnered with... Read more
Sell if holding. Engine safety override at $4.17: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.2/10. Specifically: High short interest: 20%; Elevated put/call ratio: 1.71; Below-average business quality. Chart setup: RSI 57 mid-range, Bollinger mid-band. Score 3.2/10, high confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 31d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About C4 Therapeutics, Inc.
About C4 Therapeutics, Inc.
C4 Therapeutics advances two clinical-stage targeted protein degraders built on its proprietary TORPEDO platform: cemsidomide, an IKZF1/3 degrader in Phase 2 development for multiple myeloma, and CFT8919, an EGFR L858R degrader for non-small-cell lung cancer that Betta Pharma is developing in Greater China. The Massachusetts-based company has not generated product revenue, reported a $105.0 million net loss in 2025, and held $297.1 million in cash and marketable securities at December 31, 2025.
C4 has no approved products and derives its financial runway from equity offerings, collaboration payments, and debt; an October 2025 underwritten offering raised approximately $117.0 million in net proceeds, funding operations, the company estimates, into the end of 2028. Cemsidomide, a MonoDAC-type Cereblon-based degrader, is advancing through a Phase 2 MOMENTUM trial and a Phase 1b combination trial with Pfizer-supplied elranatamab under a September 2025 collaboration agreement, while CFT8919 remains in a Betta Pharma-run Phase 1 trial covering mainland China, Hong Kong, Macau, and Taiwan under a 2023 license. Beyond the two clinical assets, C4 is building an earlier-stage discovery pipeline in inflammation, neuroinflammation, and neurodegeneration in collaboration with Merck KGaA and Roche, all originating from the same Cereblon-focused TORPEDO degrader-design platform rather than a diversified set of drug-discovery technologies.
Show full overview
C4's own disclosure underscores the binary nature of clinical-stage biotech value: the company previously shut down its CFT8634 program after a Phase 1/2 trial failed to show the desired safety and efficacy profile despite earlier preclinical and early clinical progress, the same attrition pattern that could affect cemsidomide or CFT8919 as they advance toward pivotal data. With an accumulated deficit of $738.7 million and no marketed product, C4's near-term equity value depends almost entirely on cemsidomide's Phase 2 MOMENTUM readout and CFT8919's China trial data reported back by Betta Pharma, rather than on any commercial cash flow of its own.
See also: Healthcare · Biotechnology
From C4 Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-07Recent Developments — C4 Therapeutics, Inc.
Latest news
- NEWS 12 Health Care Stocks Moving In Tuesday's Intraday Session — benzinga Jun 30, 2026 neutral
Generated 2026-07-07T13:21:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineTORPEDO platform product candidates10-K Item 1A: 'We have invested substantially all of our research and development efforts and associated financial resources into building our TORPEDO platform'
Material Events(8-K, last 90d)
- 2026-05-15Item 5.02MEDIUMChief Accounting Officer Mark Mossler will depart effective May 15, 2026, with no disagreement with the Company cited. CFO Kendra R. Adams was designated principal accounting officer effective the same date, without additional compensation for the added role.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
6 floor-breakers
Revenue shrinking — -15.0% YoY. Growth thesis broken unless recovery story develops.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Volatile — 9.0% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -297.8%. Quality floor flags this regardless of sector context.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $4.17: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.2/10. Specifically: High short interest: 20%; Elevated put/call ratio: 1.71; Below-average business quality. Chart setup: RSI 57 mid-range, Bollinger mid-band. Prior stop was $3.85. Score 3.2/10, high confidence.
Take-profit target: $5.07 (+22.5% upside). Prior stop was $3.85. Stop-loss: $3.85.
Concentration risk — Pipeline: TORPEDO platform product candidates; DATA_ISSUE: analyst_target_implausible (raw $13.33 vs price $4.14 — ratio 3.2×). Rejected, falling back to technical TP.; Quality below floor (3.5 < 4.0).
C4 Therapeutics, Inc. trades at a P/E of N/A (forward -4.1). TrendMatrix value score: 0.9/10. Verdict: Sell.
13 analysts cover CCCC with a consensus score of 4.2/5. Average price target: $13.
What does C4 Therapeutics, Inc. do?C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company using its proprietary TORPEDO platform to design...
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company using its proprietary TORPEDO platform to design small-molecule targeted protein degraders, with two clinical programs — cemsidomide for multiple myeloma and CFT8919 for EGFR-mutant lung cancer (partnered with Betta Pharma in Greater China) — plus discovery collaborations with Merck KGaA and Roche. The company has no product revenue, reported a $105.0 million net loss in 2025, and held $297.1 million in cash and marketable securities at year-end, expected to fund operations into late 2028.